Literature DB >> 22956348

Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial.

Tahereh Madani1, Ladan Mohammadi Yeganeh, Shabnam Khodabakhshi, Mohammad Reza Akhoond, Fatemeh Hasani.   

Abstract

PURPOSE: To investigate the effect of late follicular administration of low dose hCG on oocyte maturity in poor responding women undergoing intracytoplasmic sperm injection (ICSI).
MATERIALS AND METHODS: This prospective randomized pilot trial was performed on 73 poor responders undergoing ICSI, in Reproductive Biomedicine Research Center, Royan Institute, Tehran, Iran. All eligible patients underwent a GnRH-a long protocol and were randomly allocated into three study groups for ovarian stimulation: groupA received recombinant FSH alone, group B received recombinant FSH supplemented by 100 IU hCG. Group C received recombinant FSH supplemented by 200 IU hCG. The main endpoint was the number of metaphase II oocytes retrieved.
RESULTS: Of 78 poor responding patients entered to this study, 73 women were considered eligible for enrolment. Of these, 26 women were allocated to receive only recombinant FSH, 24 patients allocated to receive recombinant FSH and 100 IU hCG and 23 patients were assigned to receive recombinant FSH and 200 IU hCG. Number of oocytes retrieved were significantly higher in group B compared to group A (6.5 ± 3.3 versus 4.0 ± 2.3; P = .03). Other cycle and clinical outcomes were comparable between three groups.
CONCLUSIONS: The present study demonstrated that adding 100 IU hCG to rFSH in a GnRH agonist cycle in poor responders improve response to stimulation whereas the number of metaphase II oocytes remains comparable between groups. The existence of a possible trend toward higher mature oocytes and lower total dosage rFSH in patients received 100 or 200 IU hCG is probably due to the small sample size that means further large clinical trials in a more homogenous population is required (clinical trial registration number; NCT01509833).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956348      PMCID: PMC3510380          DOI: 10.1007/s10815-012-9854-3

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  47 in total

1.  [Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response to controlled ovarian hyperstimulation? An analysis of 142 cancellations].

Authors:  F Lamazou; F Fuchs; M Grynberg; V Gallot; E Herzog; R Fanchin; N Frydman; R Frydman
Journal:  J Gynecol Obstet Biol Reprod (Paris)       Date:  2011-08-10

2.  Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization.

Authors:  Anne K Van Horne; G Wright Bates; Randal D Robinson; Nancy J Arthur; Anthony M Propst
Journal:  Fertil Steril       Date:  2007-04-16       Impact factor: 7.329

3.  Is there an ideal stimulation regimen for IVF for poor responders and does it change with age?

Authors:  Beverley Vollenhoven; Tiki Osianlis; James Catt
Journal:  J Assist Reprod Genet       Date:  2008-11-04       Impact factor: 3.412

4.  Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.

Authors:  Karine Chung; Lewis Krey; Joseph Katz; Nicole Noyes
Journal:  Fertil Steril       Date:  2005-08       Impact factor: 7.329

Review 5.  Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility.

Authors:  Marco Filicori; Asgerally T Fazleabas; Ilpo Huhtaniemi; Peter Licht; Ch V Rao; Jan Tesarik; Marek Zygmunt
Journal:  Fertil Steril       Date:  2005-08       Impact factor: 7.329

6.  Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study.

Authors:  R Matorras; B Prieto; A Exposito; R Mendoza; L Crisol; P Herranz; S Burgués
Journal:  Reprod Biomed Online       Date:  2011-02       Impact factor: 3.828

7.  The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.

Authors:  S Burgués
Journal:  Hum Reprod       Date:  2001-12       Impact factor: 6.918

8.  Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.

Authors:  Murat Berkkanoglu; Mete Isikoglu; Donay Aydin; Kemal Ozgur
Journal:  Fertil Steril       Date:  2007-02-12       Impact factor: 7.329

9.  Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study.

Authors:  F Lisi; L Rinaldi; S Fishel; R Lisi; G Pepe; M G Picconeri; A Campbell; P Rowe
Journal:  Reprod Biomed Online       Date:  2001       Impact factor: 3.828

10.  Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.

Authors:  P Humaidan; M Bungum; L Bungum; C Yding Andersen
Journal:  Reprod Biomed Online       Date:  2004-06       Impact factor: 3.828

View more
  2 in total

Review 1.  Poor ovarian reserve.

Authors:  Padma Rekha Jirge
Journal:  J Hum Reprod Sci       Date:  2016 Apr-Jun

2.  The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation.

Authors:  Xiuxian Zhu; Jing Ye; Yonglun Fu; Ai Ai; Renfei Cai; Yun Wang; Qingging Hong; Tian Hui; Qifeng Lyu; Qiuju Chen; Yanping Kuang
Journal:  Oncotarget       Date:  2017-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.